Study of association between molecular marker expression on tumor and immunocompetent cells and sensitivity to adjuvant and neoadjuvant therapy of bladder cancer-Reference-Cited by-同舟云学术

Study of association between molecular marker expression on tumor and immunocompetent cells and sensitivity to adjuvant and neoadjuvant therapy of bladder cancer

Published:2019-07-09 Issue:2 Volume:15 Page:100-106
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Zaborskiy I. N.¹^ORCID,Ivanov S. A.¹^ORCID,Mushkarina T. Yu.¹,Karyakin O. B.¹^ORCID,Kuzmina E. G.¹,Safiullin K. N.¹,Chaykov V. S.¹^ORCID,Troyanov A. V.¹,Dementiev I. O.¹,Kasymov M. R.¹,Demyashkin G. A.²^ORCID

Affiliation:

1. A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

2. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Abstract

Use of immunotherapy in treatment of muscle-invasive bladder cancer remains the most promising method in case of impossibility of chemotherapy with cisplatin or progression during cisplatin treatment. This approach is the method of choice and can prolong patient’s life. In particular, use of checkpoint inhibitors allows to obtain effective treatment of bladder cancer. However, to prescribe immunotherapeutic medication, patient must have point of application for these drugs. Individualized approach will allow to increase treatment effectiveness and disease prognosis while maximally improving the quality of life.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference38 articles.

1. State of oncological care in Russia in 2017. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).

2. Said N. Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget 2016;7(41):67574–85. DOI: 10.18632/oncotarget.11590.

3. Volkova M.I., Matveev V.B., Medvedev S.V. et al. Clinical guidelines of diagnosis and treatment of patients with bladder cancer. Moscow, 2014. (In Russ.).

4. Clinical oncourology. Ed. B.P. Matveev. Moscow, 2011. (In Russ.).

5. Choudhury N.J., Kiyotani K., Yap K.L. et al. Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur Urol Focus 2016;2(4): 445–52. DOI: 10.1016/j.euf.2015.09.007.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local cytokine concentration in patients with non-muscle invasive bladder cancer of low malignant potential and with varying rates of recurrence;Cancer Urology;2023-02-28